Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126396021 | 12639602 | 1 | I | 20160727 | 20160810 | 20160810 | EXP | US-APOTEX-2016AP010203 | APOTEX | IGALA SB, DOMINGO A, VILLAFRANCA A, RIVERA L, GOMEZ-DASPET J.. OCTREOTIDE S ROLE IN MANAGING INTENTIONAL SULFONYLUREA OVERDOSE.. ENDOCR-REV. 2014;35(SUPPL.):NO 3 | 61.00 | YR | M | Y | 0.00000 | 20160810 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126396021 | 12639602 | 1 | PS | GLIPIZIDE. | GLIPIZIDE | 1 | Oral | 20 TABLETS | 75795 | TABLET | |||||||||
| 126396021 | 12639602 | 2 | SS | GLIPIZIDE. | GLIPIZIDE | 1 | Unknown | UNK | 75795 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126396021 | 12639602 | 1 | Intentional overdose |
| 126396021 | 12639602 | 2 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126396021 | 12639602 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126396021 | 12639602 | Hypoglycaemia | |
| 126396021 | 12639602 | Intentional overdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |